On the public citation graph

Discovery and Preclinical Evaluations of Tqb3616, a Novel Cdk4-Biased Inhibitor

https://doi.org/10.2139/ssrn.4765196
0 signed · 27 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/ijc.32020openalex-extracted
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
inferredcites →https://doi.org/10.1002/jcb.20712openalex-extracted
Beyond the cell cycle: A new role for Cdk6 in differentiation
inferredcites →https://doi.org/10.1007/s10637-014-0120-7openalex-extracted
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
inferredcites →https://doi.org/10.1007/s40262-020-00930-xopenalex-extracted
Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib
inferredcites →https://doi.org/10.1007/s40265-020-01461-2openalex-extracted
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
inferredcites →https://doi.org/10.1016/j.stem.2015.01.017openalex-extracted
CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic Stem Cells
inferredcites →https://doi.org/10.1038/nature06046openalex-extracted
Cdk1 is sufficient to drive the mammalian cell cycle
inferredcites →https://doi.org/10.1038/ncomms7769openalex-extracted
CDK1 structures reveal conserved and unique features of the essential cell cycle CDK
inferredcites →https://doi.org/10.1038/nrc2602openalex-extracted
Cell cycle, CDKs and cancer: a changing paradigm
inferredcites →https://doi.org/10.1038/s41467-020-16559-0openalex-extracted
Quantifying CDK inhibitor selectivity in live cells
inferredcites →https://doi.org/10.1038/s41523-023-00520-7openalex-extracted
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
inferredcites →https://doi.org/10.1038/s41568-022-00456-3openalex-extracted
Targeting CDK4 and CDK6 in cancer
inferredcites →https://doi.org/10.1073/pnas.0809645106openalex-extracted
Crystal structure of human CDK4 in complex with a D-type cyclin
inferredcites →https://doi.org/10.1073/pnas.0809674106openalex-extracted
The structure of CDK4/cyclin D3 has implications for models of CDK activation
inferredcites →https://doi.org/10.1093/jjco/hyz151openalex-extracted
Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer
inferredcites →https://doi.org/10.1101/2020.04.23.058347openalex-extracted
The Kinase-Dependent and Independent Functions of Cdk4 and Cdk6 Regulate Continuous Proliferation and the Exit From Quiescence Differently
inferredcites →https://doi.org/10.1126/science.abc1495openalex-extracted
CDK4 and CDK6 kinases: From basic science to cancer therapy
inferredcites →https://doi.org/10.1128/mcb.01823-08openalex-extracted
Differential Regulation of Cyclin-Dependent Kinase 4 (CDK4) and CDK6, Evidence that CDK4 Might Not Be Activated by CDK7, and Design of a CDK6 Activating Mutation
inferredcites →https://doi.org/10.1158/1535-7163.mct-16-0300openalex-extracted
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
inferredcites →https://doi.org/10.1158/2159-8290.cd-15-0894openalex-extracted
Targeting CDK4 and CDK6: From Discovery to Therapy
inferredcites →https://doi.org/10.1159/000447417openalex-extracted
Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer
inferredcites →https://doi.org/10.1177/1758835918793326openalex-extracted
Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
inferredcites →https://doi.org/10.1186/1476-4598-10-72openalex-extracted
Selective anticancer activity of a hexapeptide with sequence homology to a non-kinase domain of Cyclin Dependent Kinase 4
inferredcites →https://doi.org/10.1200/jco.2005.03.7689openalex-extracted
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
inferredcites →https://doi.org/10.21037/apm-21-1096openalex-extracted
Side effects of CDK4/6 inhibitors in the treatment of HR+/HER2− advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials
inferredcites →https://doi.org/10.3389/fonc.2021.693104openalex-extracted
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
inferredcites →https://doi.org/10.3892/br.2019.1248openalex-extracted
Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.